Summary
A.forall Development is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2024 annual accounts show equity of €39.3m and a net result of €12.3m. Equity is shrinking by about 7.3% per year across the filed financial years. Its solvency ranks better than 62% of 6,171 sector peers (NACE 64, financial year 2024). The company has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
5 holdingsHoldings 5
Source for every holding own accounts 2024
- A.forall Access Ltd.IEsubsidiaryEquity €167,848Result -€1,842100%
- Generic Pharma International LTD.IEsubsidiaryEquity €8.6mResult €4.8m100%
- Generic Specialty Pharma LTD.IEsubsidiaryEquity €13.0mResult €1.7m100%
- Milla Pharmaceuticals Inc.USsubsidiaryEquity -€464,380Result -€607,369100%
-
100%
According to the 2024 annual accounts of A.forall Development and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
3 current directorsThe board mandates are listed below; here you explore them as a network.